ANRO
Alto Neuroscience, Inc.
NYSE · Healthcare · Biotechnology · US
$30.27
−2.29%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+33.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| May 29, 2026 | Miller Andrew Craig · director | A-Award | 26,000 | $20 |
| May 14, 2026 | Sanchez Ramiro · director | A-Award | 10,958 | $25 |
| May 14, 2026 | Cox Christopher Nixon · director | A-Award | 10,958 | $25 |
| May 14, 2026 | York Gwill · director | A-Award | 10,958 | $25 |
| May 14, 2026 | Dreyfus Andrew · director | A-Award | 10,958 | $25 |
| May 14, 2026 | Manji Husseini · director | A-Award | 10,958 | $25 |
| Mar 3, 2026 | Smith Nicholas Conrad · officer: CHIEF FINANCIAL OFFICER & CBO | F-InKind | 2,806 | $20 |
| Mar 3, 2026 | Etkin Amit · director, officer: PRESIDENT AND CEO | F-InKind | 6,227 | $20 |
| Feb 13, 2026 | Etkin Amit · director, officer: PRESIDENT AND CEO | A-Award | 306,000 | $17 |
| Feb 13, 2026 | Hanley Jr. Michael Conick · officer: CHIEF OPERATING OFFICER | A-Award | 131,000 | $17 |
| Feb 13, 2026 | Savitz Adam · officer: CHIEF MEDICAL OFFICER | A-Award | 124,000 | $17 |
| Feb 13, 2026 | Smith Nicholas Conrad · officer: CHIEF FINANCIAL OFFICER & CBO | A-Award | 200,000 | $17 |
| Jan 6, 2026 | Manji Husseini · director | A-Award | 4,228 | $17 |
| Jan 6, 2026 | York Gwill · director | A-Award | 5,243 | $17 |
| Jan 6, 2026 | Cox Christopher Nixon · director | A-Award | 7,189 | $17 |
| Jan 6, 2026 | Sanchez Ramiro · director | A-Award | 3,806 | $17 |
| Aug 14, 2025 | Sanchez Ramiro · director | A-Award | 30,574 | $3.18 |
| Aug 14, 2025 | Sanchez Ramiro · director | A-Award | 3,928 | $3.18 |
| Jul 8, 2025 | Etkin Amit · director, officer: PRESIDENT AND CEO | A-Award | 247,290 | $2.35 |
| Jul 8, 2025 | Etkin Amit · director, officer: PRESIDENT AND CEO | A-Award | 223,000 | $2.35 |
| Jul 8, 2025 | Etkin Amit · director, officer: PRESIDENT AND CEO | A-Award | 215,000 | $2.35 |
| Jul 8, 2025 | Etkin Amit · director, officer: PRESIDENT AND CEO | A-Award | 34,620 | $2.35 |
| Jul 8, 2025 | Smith Nicholas Conrad · officer: CHIEF FINANCIAL OFFICER & CBO | A-Award | 202,329 | $2.35 |
| Jul 8, 2025 | Smith Nicholas Conrad · officer: CHIEF FINANCIAL OFFICER & CBO | A-Award | 135,000 | $2.35 |
| Jul 8, 2025 | Smith Nicholas Conrad · officer: CHIEF FINANCIAL OFFICER & CBO | A-Award | 90,000 | $2.35 |
| Jul 8, 2025 | Smith Nicholas Conrad · officer: CHIEF FINANCIAL OFFICER & CBO | A-Award | 44,962 | $2.35 |
| Jul 8, 2025 | Smith Nicholas Conrad · officer: CHIEF FINANCIAL OFFICER & CBO | A-Award | 33,833 | $2.35 |
| Jul 8, 2025 | Savitz Adam · officer: CHIEF MEDICAL OFFICER | A-Award | 33,008 | $2.35 |
| Jul 8, 2025 | Savitz Adam · officer: CHIEF MEDICAL OFFICER | A-Award | 22,481 | $2.35 |
| Jul 8, 2025 | Savitz Adam · officer: CHIEF MEDICAL OFFICER | A-Award | 73,000 | $2.35 |
Institutional positioning
13F filings over the trailing two quarters
New 52Increased 67Reduced 74Sold out 21
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ALPHA WAVE GLOBAL, LP | Unchanged | 3,707,757 | May 14, 2026 |
| Alpha Wave Global, LP | Unchanged | 3,707,757 | Aug 13, 2026 |
| Commodore Capital LP | Unchanged | 2,723,196 | Aug 14, 2026 |
| COMMODORE CAPITAL LP | Increased | 2,723,196 | May 15, 2026 |
| BlackRock, Inc. | Increased | 2,121,009 | Aug 7, 2026 |
| VESTAL POINT CAPITAL, LP | Reduced | 2,064,075 | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 2,009,893 | May 29, 2026 |
| PERCEPTIVE ADVISORS LLC | Reduced | 1,609,893 | Aug 14, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Increased | 1,600,000 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 1,389,477 | Aug 13, 2026 |
| Spruce Street Capital LP | Increased | 1,353,047 | Aug 13, 2026 |
| Spruce Street Capital LP | Increased | 1,325,210 | May 14, 2026 |
| Vivo Capital, LLC | Increased | 1,208,858 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,207,025 | May 15, 2026 |
| FRANKLIN RESOURCES INC | Reduced | 1,101,874 | May 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing May 29, 2026